Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04682587 · ClinicalTrials.gov registry record
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 481
- Enrollment target
NCT04682587 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 481 participants.
The verdict
NCT04682587 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 481 participants
- Enrollment target
Study Summary
To assess how dose reductions or treatment interruptions related to axitinib can be implemented to manage and resolve adverse events occurring among patients with advanced renal cell carcinoma treated with first-line axitinib in combination with avelumab or pembrolizumab
Interventions
- DRUG Pembrolizumab
- DRUG Axitinib
- DRUG Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 481 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2021-04-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04682587
The ClinicalTrials.gov registry entry for NCT04682587 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 481 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04682587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04682587 about?
NCT04682587 is a clinical study titled "To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma". To assess how dose reductions or treatment interruptions related to axitinib can be implemented to manage and resolve adverse events occurring among patients with advanced renal cell carcinoma treated with first-line axitinib in combination with avelumab or pembrolizumab
What is the current status of trial NCT04682587?
This trial is currently completed. The enrollment target is 481 participants. The study started on 2021-02-24. Estimated completion is 2021-04-05.
What interventions are being tested in trial NCT04682587?
The interventions under investigation include: Pembrolizumab (DRUG), Axitinib (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT04682587?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.